Both appear on the same standard lipid panel and both are reported in mg/dL, yet they are read in opposite ways. A higher LDL value is generally read as less favourable and a higher HDL value as more favourable, and neither number on its own describes what is happening inside an artery wall.
HDL Cholesterol measures the cholesterol carried inside high-density lipoprotein particles, not the number of those particles and not how well they work. It comes from the same blood draw as the rest of a lipid panel and is reported in mg/dL. How the test is run, what typical and optimal ranges look like, and how to read a single HDL result in context all sit on that marker page, so this guide does not repeat them. Everything below is about the comparison itself, what each particle is for, why they travel in opposite directions, why one of them carries more weight in risk estimation, and how both appear on the same report.
LDL is the delivery fleet, moving cholesterol from the liver out to the rest of the body, and the LDL value on a panel estimates how much cholesterol those delivery particles are carrying. The liver packages fat and cholesterol into very low density lipoprotein (VLDL). As VLDL unloads triglyceride into muscle and fat tissue it shrinks, becoming intermediate density lipoprotein and then LDL, a smaller and more cholesterol-rich particle. Every one of these particles carries a single large structural protein, apolipoprotein B-100, which works as the docking key for the LDL receptor on cells that need cholesterol for membranes, steroid hormones and bile acids.
That delivery job is normal and necessary. The issue is traffic volume and residence time. LDL particles are small enough to cross the inner lining of an artery, and once inside the wall some are retained, chemically modified and swallowed by immune cells, which is how plaque begins. Research suggests that LDL cholesterol, HDL cholesterol and triglycerides each affect endothelial function in different ways, with LDL contributing to the endothelial dysfunction seen in dyslipidemia 1.
That is why LDL cholesterol usually drives the conversation after a lipid panel rather than HDL. One LDL result is still only an observation. A single raised value can reflect inherited lipid handling, a recent illness, a change in body composition, thyroid function or ordinary biological variation, and it is worth repeating and reading alongside the rest of the panel before anyone draws a conclusion from it. What happens next is a decision for a clinician who can see your full history.
Those labels describe direction of travel, not two different chemicals. The cholesterol inside an HDL particle is chemically identical to the cholesterol inside an LDL particle. What differs is the vehicle carrying it and where that vehicle is headed.
Cholesterol does not dissolve in blood, so it travels inside lipoproteins, spherical particles with a fatty core wrapped in a shell of phospholipid and proteins called apolipoproteins. The apolipoproteins decide where a particle docks and what it hands over. Laboratories originally separated these particles by density, which is where the names came from. Chylomicrons are the least dense, then VLDL, then IDL, then LDL, and finally HDL, the smallest and most protein-dense of the group.
So an HDL result and an LDL result are not two readings of the same pool pulling against each other. They are estimates of how much cholesterol is riding in two different fleets with two different jobs. The good and bad shorthand is useful in a first conversation and misleading after that, because it implies that lifting one number automatically offsets the other.
It also explains an arithmetic question that confuses a lot of people, whether HDL and LDL should add up to total cholesterol. They come close, but not exactly, because total cholesterol also counts the cholesterol carried inside triglyceride-rich particles such as VLDL, which are reported in neither the HDL nor the LDL line.
LDL carries cholesterol outward from the liver to peripheral tissue, and HDL carries it in the opposite direction, from tissue back toward the liver. The return journey is called reverse cholesterol transport, and it is the single clearest difference between the two particles.
A new HDL particle begins as little more than apolipoprotein A-I with a small amount of lipid attached. It circulates, docks against cell membranes including the cholesterol-loaded immune cells inside artery walls, and accepts free cholesterol through membrane transporters. An enzyme called LCAT then converts that free cholesterol into cholesteryl ester, which sinks into the particle core, turning a flat disc into a mature sphere and freeing surface space to accept more. The loaded particle eventually hands its cargo to the liver, either directly through a liver receptor or indirectly by swapping lipid with ApoB-containing particles through cholesteryl ester transfer protein. From the liver, cholesterol can be excreted in bile.
That mechanism is the source of HDL's protective reputation. Studies indicate that low HDL cholesterol is associated with atherosclerosis risk beyond what LDL cholesterol alone accounts for, which is why HDL has been examined as a prevention target in its own right 2.
The limitation is that the HDL number on a panel measures cargo, not capability. It reports how much cholesterol is sitting inside HDL particles at the moment blood was drawn. It says nothing directly about how efficiently those particles are unloading cholesterol from an artery wall, and two people with the same HDL value can differ in that respect.
They differ in structure, signature protein, direction, and in how each number is generated and read. The table below sets the practical differences out in one place.
| Feature | LDL | HDL |
|---|---|---|
| Full name | Low-density lipoprotein | High-density lipoprotein |
| Signature protein | One apolipoprotein B-100 per particle | Apolipoprotein A-I |
| Size and density | Larger, lipid-rich, less dense | Smaller, protein-rich, more dense |
| Direction of transport | Liver outward to tissue | Tissue back toward the liver |
| What the lab value measures | Cholesterol carried inside LDL particles | Cholesterol carried inside HDL particles |
| How the value is produced | Often calculated from other panel values, direct assays also exist | Measured directly |
| Included in an ApoB measurement | Yes | No |
| Included in non-HDL cholesterol | Yes | No, it is the value subtracted |
| How a higher value is generally read | Less favourable | More favourable, within limits |
The last row is the one to hold loosely. The relationship between LDL and risk runs in one direction fairly consistently, while the relationship between HDL and risk is less linear at the upper end. A higher HDL figure is not a scorecard point that can be traded against an elevated LDL, and reading it that way is the most common mistake people make with their own panel.
Because LDL particles are the ones that enter and stay in the artery wall, while the HDL number reports cargo rather than demonstrated function. Risk accumulates when apolipoprotein B-carrying particles cross the endothelium and are retained, so any measure reflecting how many of those particles are circulating sits closer to the underlying biology than a measure of how much cholesterol is in the return fleet.
Studies indicate that apolipoprotein B relates more closely to cardiovascular risk than LDL cholesterol or non-HDL cholesterol when the three markers are compared directly 3. Research suggests that LDL contributes to endothelial dysfunction in dyslipidemia, alongside separate contributions from HDL and triglycerides 1.
There is a second reason HDL behaves less predictably as a risk marker. A low HDL value rarely travels alone. Research suggests that low HDL cholesterol frequently occurs together with LDL subclass abnormalities, and that those abnormalities contribute to the cardiovascular risk observed in people with low HDL 4. In other words, part of what a low HDL signals may be the company it keeps, including raised triglycerides and a shift toward smaller, denser LDL particles.
None of this makes HDL a throwaway number. It is a useful marker of overall metabolic pattern and it changes the way the rest of a panel reads. It simply is not a counterweight that cancels the delivery side of the ledger, and it is not the number a clinician is likely to anchor a decision to.
No. A high HDL reading does not neutralise a high LDL or a high atherogenic particle count, and it is not a reason to leave an elevated LDL unexamined. The two numbers are not a balance that nets out to a single score.
The reason sits in what each value can and cannot show. An HDL concentration describes how much cholesterol is inside HDL particles. It does not describe how well those particles accept cholesterol from cells, how quickly they deliver it to the liver, or whether they retain their other functions. Research suggests that HDL influences endothelial function through pathways that a simple cholesterol concentration does not capture 1. A high HDL value therefore describes quantity, not demonstrated performance.
There is also the question of what a very high HDL means, and the honest answer is that it depends on the person and the rest of the panel. Studies indicate that low HDL cholesterol is associated with atherosclerosis risk 2, but the inverse is not automatically true in the same way, and a high figure on its own is not a protective certificate.
This is also where composite measures need care. The LDL to HDL ratio can look reassuring purely because HDL is high, even when the absolute LDL value is well above where a clinician would want it. A ratio compresses two separate pieces of information into one, and compression hides things. Read the component numbers first, then the ratio.
Both are ways of capturing every artery-entering particle in a single number instead of looking at LDL alone. Non-HDL cholesterol is total cholesterol minus HDL cholesterol, which leaves the cholesterol carried in all apolipoprotein B-containing particles, including VLDL and IDL remnants as well as LDL. ApoB goes one step further and counts the particles themselves.
Every atherogenic lipoprotein particle carries exactly one apolipoprotein B molecule, so an ApoB measurement is effectively a particle count rather than a cargo measurement 5. That distinction matters because particles vary in how much cholesterol they carry. Two people with identical LDL cholesterol values can be carrying very different numbers of particles.
Research suggests that non-HDL cholesterol and ApoB perform at least as well as LDL cholesterol in atherosclerotic cardiovascular disease risk assessment 6. Studies indicate that ApoB and non-HDL cholesterol add information beyond LDL cholesterol in routine cardiovascular care 7. There is also a physiological argument for why that would be the case, set out in work describing the bases for ApoB's superiority over both LDL cholesterol and non-HDL cholesterol as a risk marker 5.
The practical consequence is discordance, which is what happens when the markers disagree in the same person. Evidence suggests that LDL cholesterol, non-HDL cholesterol and ApoB can diverge, and discordance analyses have compared which of them better estimates cardiovascular risk when they do 8. A person with raised triglycerides or an insulin-resistant pattern is a common example, because their LDL cholesterol can read acceptably while their particle count does not. Whether any of these extra measurements belong on your next draw is a question for a clinician who knows your history.
They appear as two separate lines in the same report, alongside total cholesterol and triglycerides, with LDL frequently calculated rather than measured. The classic calculation subtracts HDL and a triglyceride-derived estimate of VLDL cholesterol from total cholesterol, which is why a high triglyceride value or a non-fasting sample can distort a calculated LDL. Newer calculation methods and direct LDL assays both exist, and laboratories differ in which they use, so comparing an LDL result across two labs is not always comparing like with like.
HDL, by contrast, is measured directly and is the more stable of the two from one draw to the next.
| Marker | Typical lab reference range | FitScript optimal range |
|---|---|---|
| HDL cholesterol, men | 40 to 100 mg/dL | 55 to 70 mg/dL |
| HDL cholesterol, women | 50 to 100 mg/dL | 60 to 80 mg/dL |
| LDL cholesterol | Commonly reported with a desirable value below 100 mg/dL and progressively higher reported bands above that | Not listed in this guide |
These are typical lab reference ranges, and reference ranges vary by lab, age and sex. FitScript's optimal ranges are optimization targets rather than diagnostic cut-offs, so a value sitting outside one is not a diagnosis and does not mean something is wrong. Read the two numbers together with triglycerides and total cholesterol rather than in isolation, and bring the whole report to whoever is interpreting it.
A low HDL value can reflect inherited differences in how apolipoprotein A-I and HDL particles are produced and cleared, and it also tends to appear as part of a wider metabolic pattern. It is an observation about one fleet of particles, not a diagnosis of anything.
Several things commonly sit behind a low reading. Inherited variation in HDL metabolism is one. A pattern of raised triglycerides is another, because triglyceride-rich particles exchange lipid with HDL and speed up its clearance. Low physical activity, smoking, significant weight gain around the midsection and poorly controlled blood sugar all show up in the same cluster. Research suggests that low HDL cholesterol often occurs alongside LDL subclass abnormalities, and that those abnormalities contribute to the risk seen in people with low HDL 4.
The meaning of a low HDL therefore depends heavily on context. A low HDL with a high triglyceride value and a high fasting glucose reads differently from a low HDL in someone with an otherwise unremarkable panel and a strong family history of longevity.
The useful next step is not to chase the HDL number directly. It is to look at what is around it, repeat the panel if the result is new or surprising, and ask a clinician whether particle-based measures such as ApoB or non-HDL cholesterol would add anything to the picture. A result that is well outside the standard range is worth discussing with a clinician promptly rather than filed away.
A raised LDL can reflect inherited lipid handling, a shift in diet or body composition, another condition that changes cholesterol clearance, or simply a result taken at an unrepresentative moment. One elevated value identifies a question, not an answer.
Inherited causes matter more than most people expect. Familial hypercholesterolemia, in which the LDL receptor pathway works poorly, produces markedly raised LDL from childhood and tends to run in families alongside early cardiovascular events. Thyroid function influences LDL clearance, and in people with an underactive thyroid LDL often reads higher than their usual baseline. Kidney and liver conditions, pregnancy, and substantial weight change can all move the number too. Dietary pattern contributes, though its size varies a great deal between individuals.
There is one more technical possibility worth knowing about. Because LDL cholesterol is usually calculated rather than counted, a high LDL cholesterol value does not always mean a high particle count, and the two can disagree. Evidence suggests that LDL cholesterol, non-HDL cholesterol and ApoB can diverge in the same person, which is exactly the situation discordance analyses set out to examine 8.
The sensible sequence is observation, then context, then conversation. Note the value, look at triglycerides, HDL and total cholesterol alongside it, consider whether anything unusual was happening when blood was drawn, and take the result to a clinician who can decide whether it needs repeating, extending with other markers, or acting on.
Both values drift with biology, timing and laboratory method, which is why a single panel is a snapshot rather than a verdict. Understanding the sources of movement stops people over-reacting to a small change.
The main influences include the following.
The practical rule is to compare like with like. Same laboratory, same fasting state, same rough time of day, and ideally not during or immediately after an illness. If a value changes dramatically between two draws taken under different conditions, the conditions are the first thing to question. If it changes dramatically under identical conditions, that is worth raising with a clinician.
Triglycerides, non-HDL cholesterol, ApoB and lipoprotein(a) round out the lipid picture, and markers of inflammation and glucose handling explain much of the context around it. HDL and LDL answer part of the question, and the rest of the panel answers the part that matters for interpretation.
FitScript members have 150+ biomarkers tested per year, including the lipid panel and the particle-based markers, with results interpreted by Atlas, FitScript's AI health advisor, and reviewed by a licensed provider who decides whether anything further is appropriate. Whichever route you take, the value of these markers comes from testing them together and tracking them over time rather than reading one of them once.
Any result outside your laboratory's reference range, any sharp change from your own previous values, and any lipid pattern sitting next to a family history of early heart disease are all worth a conversation. So is a result that looks reassuring while symptoms or family history suggest otherwise.
A few situations deserve attention sooner rather than later. A markedly elevated LDL, particularly from a young age or with relatives who had heart attacks or strokes early, is worth discussing with a clinician promptly, because inherited lipid disorders are identifiable and the earlier they are recognised the more options exist. A very low HDL combined with high triglycerides and raised glucose markers points to a metabolic pattern worth examining as a whole. A large unexplained swing between two comparable draws is also worth raising.
What a clinician brings is everything a number cannot. Age, blood pressure, smoking status, family history, other conditions and the rest of your bloodwork all change how a lipid panel should be read, and only a licensed provider can judge whether any intervention is appropriate for you. No single value on its own identifies a disease, and no value should be ignored because another one looks good.
This article is educational and is not medical advice. Discuss your own results and any treatment decisions with a clinician or licensed provider who can review your full history.
For related reading, the arithmetic behind the two numbers is covered in is HDL plus LDL total cholesterol, the particle-versus-cargo mismatch is explored in can you have high ldl and low apob, and a common everyday question about what shifts a lipid panel is answered in does coffee raise cholesterol.
Those nicknames describe direction of travel, not two different substances. The cholesterol inside both particles is identical. LDL carries it from the liver out to tissue, where some of it can end up in artery walls, and HDL carries it back toward the liver. Useful shorthand for a first conversation, and too simple for reading your own panel.
They are not interchangeable, so the question does not really have a trade-off answer. A low LDL and a high HDL describe different things, and a favourable HDL does not offset an elevated LDL. Look at both numbers separately, alongside triglycerides and total cholesterol, and let a clinician weigh them against your age, history and other results.
A very high HDL value is not automatically a better result, and it is not a protective guarantee. The number reports how much cholesterol is inside HDL particles, not how well those particles are doing their job. If your HDL sits well above your lab's reported range, bring it to a clinician along with the rest of the panel rather than assuming it is simply good news.
Almost, but not exactly. Total cholesterol also includes the cholesterol carried inside triglyceride-rich particles such as VLDL, which appear in neither the HDL nor the LDL line. That gap is one reason non-HDL cholesterol, calculated as total cholesterol minus HDL, is reported on many panels.
It is simply LDL divided by HDL, and a lower figure is generally read as more favourable. The catch is that a ratio compresses two separate numbers into one, so it can look reassuring because HDL is high even when the absolute LDL value is not where a clinician would want it. Read the component values first, then the ratio.
It depends on the laboratory and on what is being measured. Recent food raises triglycerides, and because LDL is often calculated from triglycerides, a non-fasting sample can shift the LDL line. Follow the instructions given with your requisition, and keep conditions consistent between draws so results stay comparable.
ApoB is a measurement of the protein carried by every artery-entering lipoprotein particle, so it works as a particle count rather than a measure of cholesterol cargo. It can disagree with LDL cholesterol in the same person, particularly when triglycerides are high. Whether it belongs on your next draw is a question for a clinician who knows your history.
There is no single interval that suits everyone. Age, family history, previous results and other conditions all change how often retesting makes sense, and a clinician sets that schedule. What matters more than frequency is consistency, since comparing results from the same lab under similar conditions makes a real change easier to spot.
Treat it as a question to answer rather than a conclusion. Check whether anything unusual was going on when blood was drawn, look at triglycerides and glucose markers alongside the two values, and arrange a repeat panel under consistent conditions. Then take the full report to a clinician, who decides whether further testing or any intervention is appropriate.